Objectives. Haemophagocytic syndrome (HPS) is known as a relatively rare complication in autoimmune diseases. Here we analysed the clinical features of HPS in patients with systemic autoimmune diseases. Methods. One thousand and fourteen patients with systemic autoimmune diseases admitted to Hokkaido University Hospital from 1997 to 2007 were recruited [350 SLE, 136 RA, 98 polymyositis/dermatomyositis (PM/DM), 88 SSc, 91 vasculitis syndrome, 37 primary SS, 26 adult onset Still's disease (AOSD) and 188 other diseases]. Clinical features and treatment outcomes were retrospectively analysed. Results. Thirty cases (3.0%) fulfilled HPS criteria (progressive cytopenia in two or more lineages and haemophagocytosis in reticuloendothelial systems). Underlying diseases were SLE (18), RA (2), PM/DM (2), SSc (2), vasculitis (1), SS (2) and AOSD (3). Nineteen patients were diagnosed as having autoimmune-associated HPS, eight infection-associated, one drug-induced and one developed HPS after haematopoietic stem cell transplantation. For the treatment of HPS, high-dose corticosteroid monotherapy was given in 26 cases, being effective in 12 (46%). Ten out of 15 patients with corticosteroid-resistant autoimmune-associated HPS were treated with CsA, cyclophosphamide or tacrolimus, leading to the remission in 80%. The overall mortality rate was 20%. Multivariate analysis showed that the presence of infections and CRP level >50 mg/l on HPS related with poor prognosis. Conclusions. The prevalence of HPS among in-hospital patients with systemic autoimmunity is not ignorable. Administration of immunosuppressants was effective in cases with autoimmune-associated HPS, whereas prognosis was poor in infection-associated HPS.
Introduction
Haemophagocytic syndrome (HPS) is a clinicopathological entity characterized by the activation of macrophages and/or histiocytes with prominent haemophagocytosis in bone marrow and other reticuloendothelial systems [1] . Clinical features of HPS include fever, cytopenia, liver enzyme elevation, hepatosplenomegaly, lymphadenopathy and coagulopathy. HPS comprises primary (hereditary) and reactive forms. Primary HPS is observed mostly in infants, represented by cases with familial haemophagocytic lymphohistiocytosis (FHL), Chediac-Higashi syndrome, Griscelli syndrome and X-linked lymphoproliferative syndrome. Reactive HPS occurs in situations such as infections, malignant lymphomas, autoimmune diseases and administration of certain drugs [2] [3] [4] . In rare cases, HPS occurs after haematopoietic stem cell or organ transplantations [5] [6] [7] [8] [9] [10] [11] [12] .
Among the systemic autoimmune diseases, SLE is the most common underlying disease for HPS. In 1991, Wong et al. [13] proposed a disease entity of acute lupus haemophagocytic syndrome, in which haemophagocytosis occurs in association with the SLE flare and the corticosteroid therapy was effective in those cases. After Kumakura et al. [2] reported cases of reactive HPS associated with other autoimmune diseases such as adultonset Still's disease (AOSD), MCTD and Evans syndrome, the concept has expanded to autoimmune-associated haemophagocytic syndrome (AAHS). Later on, it has been recognized that HPS and AOSD share the pathophysiology representing excessive activation of macrophages with cytokine overproduction [4, 8] . The prevalence of HPS in SLE and AOSD was reported as 0.9-2.4% and 12%, respectively, by some previous studies [4, 13, 14] . Recently, Dhote et al. [3] retrospectively investigated 26 patients with reactive HPS in adult autoimmune diseases in a French multicentre study and reported that the overall mortality was 38.5%. However, epidemiology of HPS in systemic autoimmunity has not been established, and clinical profiles of such patients are still obscure. To clarify the prevalence and the prognosis of HPS complicated with systemic autoimmune diseases, we retrospectively analysed the clinical features of HPS in the inhospital patients with systemic autoimmune diseases in our hospital.
Patients and methods

Patients and data
One thousand and fourteen consecutive patients with systemic autoimmune diseases [350 SLE, 136 RA, 98 polymyositis/ dermatomyositis (PM/DM), 88 SSc, 91 systemic vasculitis syndrome, 37 primary SS, 26 AOSD and 188 other autoimmune diseases] admitted to Hokkaido University Hospital during the period from January 1997 to December 2007 were recruited. All patients received in-hospital treatment for more than 7 days. RA was diagnosed using the ARA 1987 revised criteria [15] . Diagnosis of SLE was made according to the revised classification criteria of ACR [16] . PM/DM and SSc were diagnosed according to the diagnostic criteria proposed by Bohan and Peter [17] and to the preliminary criteria for the classification of SSc proposed by ARA, respectively [18] . AOSD was diagnosed using preliminary criteria for classification of AOSD proposed by Yamaguchi et al. [19] . Vasculitis syndrome was diagnosed according to the ACR 1990 criteria [20, 21] , and SS using the revised European criteria [22] . Patients having malignant diseases were excluded from this study. Diagnoses of these autoimmune diseases were made or had already been made when our patients were in hospital.
Diagnosis of HPS was made in cases of otherwise unexplained progressive cytopenia affecting at least two cell lineages, and bone marrow showing mature histiocytes with prominent haemophagocytosis and/or haemophagocytosis in liver, spleen or lymph nodes [1, 3] . Diagnosis of AAHS was made according to the criteria proposed by Kumakura et al. [23] , which require (i) cytopenia affecting at least two lineages, (ii) histiocytic haemophagocytosis in bone marrow or other reticuloendothelial systems, (iii) active phase of underlying disease at the occurrence of haemophagocytosis and (iv) exclusion of other reactive HPS such as virus or malignancy-associated HPS. Diagnosis of HPS/AAHS was made when these patients were under treatment.
Medical records of these patients were retrospectively reviewed and the following clinical conditions were evaluated: underlying diseases, triggers for the HPS onset, clinical features including fever, splenomegaly, lymphadenopathy and neuropsychiatric symptoms. Laboratory data such as complete blood cell (CBC) counts, serum liver transaminase levels, serum ferritin levels, serum lactate dehydrogenase (LDH) levels, serum CRP levels, serum triglyceride levels and plasma D-dimer levels were collected as well at the time of HPS diagnosis. Presence of active bacterial infections was diagnosed upon positive blood, urine or sputum cultures. CMV infection was defined by positive C7-HRP antigenaemia with at least one of the following clinical manifestations: fever, pneumonia, cytopenia or liver damage [24] . Pneumocystis jirovecii pneumonia (PCP) was diagnosed by CT scan with positive staining of bronchoalveolar fluid and/or positive PCR product from a respiratory specimen [25] . Disseminated intravascular coagulation (DIC) was diagnosed according to the algorithm proposed by International Society on Thrombosis and Haematostasis [26] . Lupus disease activity was evaluated using BILAG index [27] . Remission was defined as returning to >80% of the patients' baseline CBC. Sex, age, duration of underlying diseases, clinical manifestations, presence of infections and laboratory data were explored for relationships with mortality.
This retrospective observation study has been approved by the ethical committee of Hokkaido University Hospital.
Statistical analysis
All factors were categorized, and then the relations with outcomes were examined using Fisher's exact test. P-values were further corrected by multiplying by the number of factors (n ¼ 16) investigated (corrected P). The relation between global BILAG score and response to corticosteroids was examined using Mann-Whitney's U-test.
Results
Prevalence of HPS
Of 1014 in-hospital patients recruited in this study, 30 cases (3.0%) were diagnosed as HPS. The HPS patients included 24 females, and the mean age of HPS onset was 43 yrs (range 19-71 yrs) at the diagnosis of HPS. The mean duration of underlying autoimmune diseases was 5.7 yrs (from 0 months to 29 yrs) at the diagnosis of HPS. HPS was the most prevalent in patients with AOSD, followed by SS and SLE groups (Table 1) . Nineteen patients (63% of HPS, 1.9% of autoimmune diseases) were diagnosed as having AAHS. AAHS was the most frequent in patients with AOSD (7.7%), followed by those with SLE (4.6%). Eight cases (27% of HPS, 0.8% of autoimmune diseases) were diagnosed as infection-associated HPS (IAHS). The remaining three patients had neither infection nor exacerbation of autoimmune diseases.
Clinical features of HPS
The clinical manifestations of 30 patients with HPS are illustrated in Table 2 . At the time when the diagnosis of HPS was made, fever at !388 was observed in 87% of the patients. Neuropsychiatric manifestations such as coma, seizure, meningeal irritation signs, mood disorder, cognitive dysfunction, delirium and psychosis were noted in nine cases (30%). Leukopenia (<4.0 Â 10 9 /l), anaemia (haemoglobin <115 g/l) or thrombocytopenia (<150 Â 10 9 /l) was found in 87, 83 or 87%, respectively. CRP was elevated in 83% of the patients. Liver enzyme elevation (aspartate aminotransferase or LDH), more than two times the upper normal limit, was observed in 60%. Median ferritin level was 980 ng/ml (range 17-27 842 ng/ml). Elevated plasma D-dimer levels were recorded in 96%, and overt DIC (DIC score !5) was noted in two patients (Patients 24 and 30). 
Triggers for HPS onset
Treatments and outcomes
Treatments and outcomes are illustrated in Table 3 Monotherapy with high-dose corticosteroid was given as an initial treatment in all of the remaining 26 cases (including methylprednisolone pulse therapy in 24 patients), being effective in 12 (46%). Four patients were lost due to infectious diseases. In 10 corticosteroid-resistant AAHS patients, immunosuppressants were introduced [oral/intravenous CsA in seven patients and intravenous cyclophosphamide pulse therapy (IVCY) in three cases. Two patients resistant to CsA received tacrolimus, resulting in remission], leading to remission in eight cases (80%). In a lupus patient (Patient 14) with HPS, glomerulonephritis and pericarditis with uncontrollable massive pericardial effusion, disease activity was not reduced by the treatment with high-dose corticosteroid including corticosteroid pulse therapy and IVCY. This patient died of multiple organ failure that is attributable to active SLE. In another lupus patient (Patient 10), HPS was resistant to corticosteroid pulse therapy, CsA and vincristine. Afterwards, rituximab was introduced in another hospital, resulting in remission. Four patients (Patients 9, 24, 28 and 30) did not receive additional immunosuppressants because they had active infection. In these cases, infectious diseases did not arrive at remission, resulting in death. In Patient 9, HPS was triggered by Enterococcus faecalis-induced septicaemia. Patient 24 suffered from bacterial pneumonia. In Patient 28, complication of CMVinduced HPS and CMV/aspergillus pneumonia was lethal. Patient 30, in whom herpes simplex virus was the suspicious cause of HPS, died of DIC.
For supportive therapies, eight patients received G-CSF when neutrophil counts were <0.5 Â 10 9 /l. -Globulin was administered in five patients with severe infections. Plasma exchange was performed in Patient 18 for concomitant thrombotic microangiopathy that developed after corticosteroid pulse therapy for HPS, with preferable outcome.
In our study, 54% of all HPS cases, including 56% of AAHS cases, were resistant to corticosteroids. The overall mortality rate was 20% (6/30) in our series. Mortality rate of AAHS was 5.3% (1/19), whereas that of IAHS was 63% (5/8).
Lupus activity and HPS
Clinical data of the 18 SLE patients are illustrated in Table 4 . SLE patient group comprised 15 females, with mean age of 34 (range 19-60) yrs. Mean disease duration at HPS diagnosis was 7.1 yrs, ranging from 0 months to 20 yrs. In all AAHS patients, the median global BILAG score was 24 (range 12-46), Grade B or higher disease-scoring items in more than one component being noted. Among 16 AAHS patients with SLE, there was no significant difference between global BILAG scores in corticosteroid responders and those in non-responders (P ¼ 0.383).
Risk factors for poor prognosis
Univariate analysis showed that age over 50 yrs, the presence of infection (IAHS), leucocyte count <0.5 Â 10 9 /l, platelet count <50 Â 10 9 /l and CRP level <50 mg/l at the onset of HPS were related with mortality, as shown in Table 5 . Multivariate analysis confirmed the correlation of the presence of infection and high CRP level to the poor prognosis.
Discussion
Our series showed the prevalence of HPS in patients with systemic autoimmune diseases and demonstrated that a variety of diseases could underlie HPS. The frequency of AAHS was 4.6% in SLE patients and 7.7% in AOSD patients, being compatible with the previous reports [13] . Most of the HPS in other autoimmune diseases were IAHS. Considering the report by Dhote et al. [3] that almost all of HPS in systemic autoimmune diseases other than SLE and AOSD was complicated by infectious events, our data confirm that AAHS is rarely found in other systemic autoimmune diseases.
We found that 9/30 (30%) patients had neurological diseases. Although neurological abnormalities are documented mainly in FHL in childhood [28] , few have been described in adult cases, especially in AAHS [29] . Previous studies have documented that $30-70% of HPS patients (mainly FHL) show neurological abnormalities such as seizures, conscious disorder, hemiparesis, nuchal rigidity and ataxia. Cytokines and other neurotoxic factors secreted by leucocytes and the microglial cells may be responsible for the cause of these neurological manifestations [30] . Although neurological involvement in our series of adult patients was not as frequent as that reported in FHL cases, we propose that neurological abnormalities are still one of the major symptoms in adult HPS patients.
Treatment strategy has not been fully established in HPS complicated with systemic autoimmune diseases. Corticosteroid monotherapy has been preferably administered for AAHS, based on the report by Wong et al. [13] in which corticosteroid was uniformly effective in HPS complicated with SLE. According to the multicentre report of 26 autoimmune cases, 19 were treated with corticosteroid alone and additional IVCY was administrated in 3 cases [3] . In the present report, 12 AAHS patients were treated with high-dose corticosteroid without immunosuprressants and 10 AAHS patients received immunosuppressive agents. Additional immunosuppressants in corticosteroid-resistant AAHS were effective in 80%. Nine out of 16 (56%) AAHS patients with SLE were resistant to corticosteroid monotherapy in our study, more frequent than previously reported (0-14%) [13, 14] . All of the corticosteroid-resistant acute lupus HPS patients in our series received CsA, IVCY or tacrolimus, being effective in seven out of nine (78%). Thus, we propose to introduce early and appropriate immunosuppressive treatment in corticosteroid-resistant AAHS cases. Although IVCY and CsA were equally effective in our cases, we prefer CsA to IVCY in two reasons. First, anti-cytokine effect in CsA is acceptable for the treatment of HPS, in which hypercytokinaemia is one of the basic aetiologies in this syndrome. Second, bone marrow suppression can be induced by IVCY, which may evoke serious infection in immunocompromised patients. The treatment of IAHS presents difficulties and resulted in poor outcome compared with non-IAHS. For EBV-associated HPS, combination chemotherapy and immunotherapy are recommended as an initial treatment, whereas aciclovir does not appear to be useful [1, 31] . For IAHS associated with other viruses and microbes, treatment protocols have not been established. In general, treatments of the underlying infection with supportive therapies, including G-CSF and -globulin, are recommended. However, the efficacy of such treatments is still obscure.
We suggest that the presence of infections and high CRP level are related with mortality. There have been several reports concerning the risk factors for poor prognosis in patients with HPS. Kaito et al. [32] analysed 34 patients with HPS (13 with haematological malignancies or viral infections) and concluded that risk factors associated with death were age over 30 yrs, presence of DIC, increased ferritin and 2 -microglobulin or anaemia accompanied by thrombocytopenia and jaundice. Takahashi et al. [33] retrospectively analysed 52 adult HPS patients and reported that the prognosis depended on their underlying diseases, malignant lymphoma and opportunistic infections.
In the autoimmune setting, (i) absence of lymphadenopathy, (ii) thrombocytopenia (<50 Â 10 9 /l), (iii) corticosteroid therapy at the time of HPS diagnosis, were listed as poor prognostic factors [3] . Taking these studies and our study together, infections seem to be the common risk factor in adult HPS patients. In this study, high CRP levels were associated with mortality and with infection (P ¼ 0.02; Mann-Whitney U-test), thus high CRP level may relate to infection rather than to HPS itself. Although this study provides novel information/suggestions for the treatment of HPS in autoimmune diseases, it has to be noted that retrospective observation studies have some shortcomings in the evaluation of the patients' clinical features. Further studies, especially randomized prospective trials will be necessary to establish better management for the affected patients.
In conclusion, our study has clarified the prevalence of HPS in in-hospital patients with systemic autoimmune diseases. Among these patients, the prognosis was better in patients with AAHS than those with IAHS, although the presence of infections and high CRP level increase the risk for poor prognosis.
